-1.png)
Neurológia pre prax 4/2021
CGRP inhibitors and gastrointestinal tract
CGRP antibodies block the vasodilating effect of CGRP and belong to the most potent antimigraine drugs available. The CGRP receptors are present in many tissues, including the gastrointestinal tract. CGRP is thought to be involved in the regulation of gastrointestinal motility, secretion, resorption and blood flow. Blockade of his action may result in a number of adverse effects. For example, a higher incidence of constipation after erenumab (anti-CGRP) has been reported. Hypothetically, these drugs may also impair gastroduodenal ulcerations healing, course of the inflammatory bowel disease or the gastric emptying rate.
Keywords: anti-CGRP, migraine, gastrointestinal tract
